{"preliminary_commentary":{"by_channel":{"x_thread":20,"podcast":4,"youtube":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05614739\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-14T08:51:11.411Z","note":"Automated from the 24 newest of 27 indexed sources (Feb 2025 – Nov 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":24,"text":"- Whether FGFR3 selectivity avoids erdafitinib's hyperphosphatemia, retinal and nail toxicities\n- Whether adding vepugratinib to first-line enfortumab vedotin plus pembrolizumab adds benefit in FGFR3-altered disease\n- Whether vepugratinib is active after progression on enfortumab vedotin plus pembrolizumab","kind":"questions"},"drugs_tested":[["vepugratinib (LOXO-435)"],["vepugratinib (LOXO-435)","pembrolizumab","enfortumab vedotin"],["vepugratinib (LOXO-435)","trastuzumab deruxtecan"]],"indication":"advanced solid tumors with FGFR3 alterations","name":"FORAGER-1","nct_id":"NCT05614739","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=forager-1-nct05614739. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"FORAGER-1","arms":[{"description":"Vepugratinib administered orally","label":"Phase 1a: Cohort A1 Vepugratinib Monotherapy Dose Escalation","type":"EXPERIMENTAL"},{"description":"Vepugratinib administered orally","label":"Phase 1a: Cohort A2 Vepugratinib Monotherapy Dose Optimization","type":"EXPERIMENTAL"},{"description":"Vepugratinib administered orally","label":"Phase 1b: Cohort B1, B2, B4, C1, and D1 Vepugratinib Monotherapy Dose Expansion","type":"EXPERIMENTAL"},{"description":"Vepugratinib administered orally in combination with pembrolizumab administered IV and enfortumab vedotin administered IV","label":"Phase 1b: Cohort B5 Vepugratinib Plus Pembrolizumab Plus Enfortumab Vedotin","type":"EXPERIMENTAL"},{"description":"Vepugratinib administered orally in combination with pembrolizumab administered IV and enfortumab vedotin administered IV","label":"Phase 1b: MIBC Cohort B6 Vepugratinib Plus Pembrolizumab Plus Enfortumab Vedotin","type":"EXPERIMENTAL"},{"description":"Vepugratinib administered orally in combination with trastuzumab deruxtecan administered IV","label":"Experimental: Phase 1b: Cohort B7 Vepugratinib Plus Trastuzumab Deruxtecan","type":"EXPERIMENTAL"},{"description":"Vepugratinib administered orally","label":"Phase 1b: NMIBC Cohort B8 Vepugratinib Monotherapy Dose Expansion","type":"EXPERIMENTAL"},{"description":"Vepugratinib Plus Midazolam Plus Digoxin Plus Rosuvastatin (Lead-In Only) followed by Vepugratinib Monotherapy\n\nVepugratinib administered orally\n\nMidazolam with digoxin with rosuvastatin administered orally once per cycle for 2 cycles.","label":"Phase 1b: Cohort D2 (Drug to Drug Interaction)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-06","type":"ESTIMATED"},"conditions":["Urinary Bladder Neoplasms","Neoplasm Metastasis","Ureteral Neoplasms"],"enrollment":{"count":677,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Vepugratinib","otherNames":["LY3866288","LOXO-435"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":[],"type":"DRUG"},{"name":"enfortumab vedotin","otherNames":[],"type":"DRUG"},{"name":"Trastuzumab Deruxtecan","otherNames":[],"type":"DRUG"},{"name":"Midazolam","otherNames":[],"type":"DRUG"},{"name":"Digoxin","otherNames":[],"type":"DRUG"},{"name":"Rosuvastatin","otherNames":[],"type":"DRUG"}],"last_update":"2026-11-04","lead_sponsor":"Eli Lilly and Company","official_title":"FORAGER-1: A Phase 1, Open-Label, Multicenter Study of Vepugratinib (LY3866288; LOXO-435) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer and Muscle Invasive Bladder Cancer With FGFR3 Alterations","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-06","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall Response Rate (ORR)","timeFrame":"Up to Approximately 30 Months or 2.5 Years"},{"measure":"Pharmacokinetics (PK) of Vepugratinib: Area Under the Concentration versus Time Curve (AUC)","timeFrame":"Up to 2 Months"},{"measure":"PK of Midazolam, Rosuvastatin, and Digoxin Administered Alone and in the Presence of Vepugratinib: Area Under the Concentration versus Time Curve (AUC[0-inf])","timeFrame":"Up to 2 Months"},{"measure":"Complete Response Rate (CRR) in Participants with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG IR NMIBC)","timeFrame":"Up to approximately 24 months or 5 years"}],"references":[],"start_date":{"date":"2023-01-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3","url":"https://clinicaltrials.gov/study/NCT05614739"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/forager-1-nct05614739"}